Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

BACKGROUND: Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to dra...

Descripción completa

Detalles Bibliográficos
Autores principales: Methy, Nicolas, Bedenne, Laurent, Bonnetain, Franck
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904280/
https://www.ncbi.nlm.nih.gov/pubmed/20537166
http://dx.doi.org/10.1186/1471-2407-10-277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904280/
https://www.ncbi.nlm.nih.gov/pubmed/20537166
http://dx.doi.org/10.1186/1471-2407-10-277

Ejemplares similares